Front Page News
Cure SMA Awards $140,000 Grant to Arthur Burghes, PhD, The Ohio State University
Cure SMA has awarded a $140,000 research grant to Arthur Burghes, PhD, at The Ohio State University, for his project, “Identification of SMA modifiers and […]
Read More ›Cure SMA Releases Care Series Booklet on Insurance
Cure SMA is excited to announce the launch of our newest care series booklet, Choice and Connection to Care: A Health Insurance Roadmap for People […]
Read More ›SMA is Submitted to the Federal Newborn Recommended Uniform Screening Panel (RUSP)
Cure SMA and the SMA Newborn Screening Coalition are excited to announce we have completed the submission of SMA to the Recommended Uniform Screening Panel […]
Read More ›Announcing an Evening of Wonder at Magic Kingdom Park
Just added to this year’s conference schedule: Saturday night at Magic Kingdom Park! We are excited to announce that each conference attendee will get to […]
Read More ›Cure SMA to Host Webinar with the FDA and Patient Advocates
Cure SMA is pleased to announce a new webinar on interactions between the FDA and the SMA community. The webinar will be held on March […]
Read More ›Registration Opens for the SMA Patient-Focused Drug Development Meeting with the FDA
Registration is now open for the SMA Patient-Focused Drug Development (PFDD) meeting with the FDA. The PFDD meeting will be held at the College Park […]
Read More ›Spinraza Access Update Webinar
On Tuesday, February 14, at 1:00pm EST (10:00am PST/11:00am MST/12:00pm CST), Cure SMA hosted a webinar updating the community on the status of Spinraza access. […]
Read More ›Cure SMA Launches Community Survey to Address Urgent and Important Issues in SMA Treatment
For the past several years, we’ve been working to collect data and information on our community’s experiences, goals, hopes and challenges. We know that the […]
Read More ›Biogen Presents New ENDEAR Data Showing SPINRAZA (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation
Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA™ (nusinersen), which demonstrated a statistically significant reduction in the risk of death or […]
Read More ›Updated SMA Drug Pipeline Released as First Commercial Patient Receives Spinraza
With the news today that the first-ever patient has received the first commercial Spinraza dose, we are releasing an updated version of our SMA drug […]
Read More ›